115 related articles for article (PubMed ID: 21287338)
1. Depletion of human regulatory T cells.
Hobeika AC; Morse MA; Osada T; Peplinski S; Lyerly HK; Clay TM
Methods Mol Biol; 2011; 707():219-31. PubMed ID: 21287338
[TBL] [Abstract][Full Text] [Related]
2. Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.
Morse MA; Hobeika AC; Osada T; Serra D; Niedzwiecki D; Lyerly HK; Clay TM
Blood; 2008 Aug; 112(3):610-8. PubMed ID: 18519811
[TBL] [Abstract][Full Text] [Related]
3. Upfront denileukin diftitox as in vivo regulatory T-cell depletion in order to enhance vaccination effects in a canine allogeneic hematopoietic stem cell transplantation model.
Knueppel A; Lange S; Altmann S; Sekora A; Knuebel G; Vogel H; Lindner I; Freund M; Junghanss C
Vet Immunol Immunopathol; 2012 Jan; 145(1-2):233-40. PubMed ID: 22173275
[TBL] [Abstract][Full Text] [Related]
4. IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity.
Litzinger MT; Fernando R; Curiel TJ; Grosenbach DW; Schlom J; Palena C
Blood; 2007 Nov; 110(9):3192-201. PubMed ID: 17616639
[TBL] [Abstract][Full Text] [Related]
5. Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents.
de Vries IJ; Castelli C; Huygens C; Jacobs JF; Stockis J; Schuler-Thurner B; Adema GJ; Punt CJ; Rivoltini L; Schuler G; Coulie PG; Lucas S
Clin Cancer Res; 2011 Feb; 17(4):841-8. PubMed ID: 21177412
[TBL] [Abstract][Full Text] [Related]
6. Diphtheria toxin-based recombinant murine IL-2 fusion toxin for depleting murine regulatory T cells in vivo.
Wei M; Marino J; Trowell A; Zhang H; Stromp Peraino J; Rajasekera PV; Madsen JC; Sachs DH; Huang CA; Benichou G; Wang Z
Protein Eng Des Sel; 2014 Sep; 27(9):289-95. PubMed ID: 25147093
[TBL] [Abstract][Full Text] [Related]
7. Comparative methodologies of regulatory T cell depletion in a murine melanoma model.
Matsushita N; Pilon-Thomas SA; Martin LM; Riker AI
J Immunol Methods; 2008 Apr; 333(1-2):167-79. PubMed ID: 18295790
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
[TBL] [Abstract][Full Text] [Related]
9. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
Klages K; Mayer CT; Lahl K; Loddenkemper C; Teng MW; Ngiow SF; Smyth MJ; Hamann A; Huehn J; Sparwasser T
Cancer Res; 2010 Oct; 70(20):7788-99. PubMed ID: 20924102
[TBL] [Abstract][Full Text] [Related]
10. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
[TBL] [Abstract][Full Text] [Related]
11. Transient T cell depletion causes regression of melanoma metastases.
Rasku MA; Clem AL; Telang S; Taft B; Gettings K; Gragg H; Cramer D; Lear SC; McMasters KM; Miller DM; Chesney J
J Transl Med; 2008 Mar; 6():12. PubMed ID: 18334033
[TBL] [Abstract][Full Text] [Related]
12. Superior depletion of alloreactive T cells from peripheral blood stem cell and umbilical cord blood grafts by the combined use of trimetrexate and interleukin-2 immunotoxin.
Szabolcs P; Park KD; Marti L; Deoliveria D; Lee YA; Colvin MO; Kurzberg J
Biol Blood Marrow Transplant; 2004 Nov; 10(11):772-83. PubMed ID: 15505608
[TBL] [Abstract][Full Text] [Related]
13. A comparison of an anti-CD25 immunotoxin, Ontak and anti-CD25 microbeads for their ability to deplete alloreactive T cells in vitro.
Vaclavkova P; Cao Y; Wu LK; Michalek J; Vitetta ES
Bone Marrow Transplant; 2006 Mar; 37(6):559-67. PubMed ID: 16444279
[TBL] [Abstract][Full Text] [Related]
14. Targeted therapy to the IL-2R using diphtheria toxin and caspase-3 fusion proteins modulates Treg and ameliorates inflammatory colitis.
Yarkoni S; Sagiv Y; Kaminitz A; Farkas DL; Askenasy N
Eur J Immunol; 2009 Oct; 39(10):2850-64. PubMed ID: 19735074
[TBL] [Abstract][Full Text] [Related]
15. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2.
Berntsen A; Brimnes MK; thor Straten P; Svane IM
J Immunother; 2010 May; 33(4):425-34. PubMed ID: 20386464
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of denileukin diftitox IL-2 immunotoxin on NK and regulatory T cells in nonhuman primates.
Yamada Y; Aoyama A; Tocco G; Boskovic S; Nadazdin O; Alessandrini A; Madsen JC; Cosimi AB; Benichou G; Kawai T
J Immunol; 2012 Jun; 188(12):6063-70. PubMed ID: 22586034
[TBL] [Abstract][Full Text] [Related]
17. IFNα Augments Clinical Efficacy of Regulatory T-cell Depletion with Denileukin Diftitox in Ovarian Cancer.
Thibodeaux SR; Barnett BB; Pandeswara S; Wall SR; Hurez V; Dao V; Sun L; Daniel BJ; Brumlik MJ; Drerup J; Padrón Á; Whiteside T; Kryczek I; Zou W; Curiel TJ
Clin Cancer Res; 2021 Jul; 27(13):3661-3673. PubMed ID: 33771857
[TBL] [Abstract][Full Text] [Related]
18. Efficient Treg depletion induces T-cell infiltration and rejection of large tumors.
Li X; Kostareli E; Suffner J; Garbi N; Hämmerling GJ
Eur J Immunol; 2010 Dec; 40(12):3325-35. PubMed ID: 21072887
[TBL] [Abstract][Full Text] [Related]
19. Depletion of CD4+CD25+ regulatory T cells enhances interleukin-2-induced antitumor immunity in a mouse model of colon adenocarcinoma.
Imai H; Saio M; Nonaka K; Suwa T; Umemura N; Ouyang GF; Nakagawa J; Tomita H; Osada S; Sugiyama Y; Adachi Y; Takami T
Cancer Sci; 2007 Mar; 98(3):416-23. PubMed ID: 17270031
[TBL] [Abstract][Full Text] [Related]
20. YB-1 immunization combined with regulatory T-cell depletion induces specific T-cell responses that protect against neuroblastoma in the early stage.
Zheng J; Liu P; Yang X
Acta Biochim Biophys Sin (Shanghai); 2012 Dec; 44(12):1006-14. PubMed ID: 23169344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
